SYMBA.OB: Summary for SYMBOLLON PHARM CL A - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:32am EST - Canadian Markets open in 2 hours and 58 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Symbollon Pharmaceuticals Inc. (SYMBA.OB)

On Feb 9: 0.11 USD 0.00 (0.00%)

MORE ON SYMBA.OB

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

SYMBOLLON PHARM CL A (OTC BB:SYMBA.OB) Delayed quote data

Last Trade:	0.11 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	0.11
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	N/A

Day's Range:	N/A - N/A
52wk Range:	0.02 - 0.94
Volume:	0
Avg Vol (3m):	9,335.94
Market Cap:	3.02M
P/E (ttm):	N/A
EPS (ttm):	-0.03
Div & Yield:	N/A (N/A%)

Symbollon Pharmaceuticals Inc. (SYMBA.OB)

1d 5d 3m 6m 1y 2y 5y max

Add SYMBA.OB to Portfolio

Download Data

HEADLINES

•	The Sylk(R) Health and Personal Care Product Line to Be Acquired by Symbollon
	Marketwire (Thu, Feb 4)

•	Woman's Breast Health Supplement, IoGen(TM), Available to Public in February From Symbollon Pharmaceuticals
	Marketwire (Thu, Jan 21)

•	Symbollon Retains Atech Solutions to Enhance Web Presence and Build Retail Site for the Sales of IoGen
	Business Wire (Tue, Jan 19)

•	Womens Breast Health Supplement to Be Launched by Symbollon
	Business Wire (Tue, Jan 12)

•	SYMBOLLON CORP Files SEC form 8-K, Unregistered Sale of Equity Securities, Financial Statements and Exhibits
	EDGAR Online (Wed, Dec 30)

•	SYMBOLLON CORP Financials
	EDGAR Online Financials (Tue, Nov 24)

•	SYMBOLLON CORP Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Thu, Oct 8)

•	Symbollon Pharmaceuticals Announces Agreement With Integra Labs, Inc. for Distribution of IoGen(TM)
	Marketwire (Tue, Jul 7)

•	SYMBOLLON CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities
	EDGAR Online (Wed, Jul 1)

•	Symbollon Pharmaceuticals Announces 2008 Year-End Results
	Marketwire (Tue, Mar 31)

More Headlines for SYMBA.OB...

ANALYST

EPS Est (next year) (Dec-69) :	N/A
EPS Est (in 2 years) (Dec-69) :	N/A
Avg Rec (current)*:	N/A
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Symbollon Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses.

Full Company Profile

Add to Portfolio

Email to a Friend

•